Active, not recruitingPhase 2NCT04097470
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
Studying Acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Principal Investigator
- Gerwin Huls, ProfUMCG / HOVON
- Intervention
- Decitabine(drug)
- Enrollment
- 140 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2019 – 2026
Study locations (30)
- BE-Antwerpen-ZNASTUIVENBERG, Antwerp, Belgium
- BE-Haine-Saint-Paul-JOLIMONT, Haine-Saint-Paul, Belgium
- BE-Roeselare-AZDELTA, Roeselare, Belgium
- DE-Magdeburg-OVGU, Magdeburg, Germany
- NL-Den Bosch-JBZ, 's-Hertogenbosch, Netherlands
- NL-Amersfoort-MEANDERMC, Amersfoort, Netherlands
- NL-Amsterdam-OLVG, Amsterdam, Netherlands
- NL-Amsterdam-VUMC, Amsterdam, Netherlands
- NL-Arnhem-RIJNSTATE, Arnhem, Netherlands
- NL-Breda-AMPHIA, Breda, Netherlands
- NL-Delft-RDGG, Delft, Netherlands
- NL-Doetinchem-SLINGELAND, Doetinchem, Netherlands
- NL-Dordrecht-ASZ, Dordrecht, Netherlands
- NL-Ede-ZGV, Ede, Netherlands
- NL-Eindhoven-CATHARINA, Eindhoven, Netherlands
- +15 more locations on ClinicalTrials.gov
Collaborators
Swiss Cancer Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04097470 on ClinicalTrials.govOther trials for Acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07493538MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07392242A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT07075016Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive ChemotherapyStichting Hemato-Oncologie voor Volwassenen Nederland
- RECRUITINGPHASE1NCT06649227Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19University Hospital, Lille
- RECRUITINGNANCT07237230Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid LeukemiaDonghua Zhang
- RECRUITINGPHASE1, PHASE2NCT06969430A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)Debiopharm International SA
- RECRUITINGNCT06899581Gut Health in Children With CancerGreat Ormond Street Hospital for Children NHS Foundation Trust
- RECRUITINGPHASE2NCT06783790Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, China